[PHP346] Market Access for Pharmaceuticals In Europe: Future Perspectives
2015 Value in Health
Rémuzat, C. | Kornfeld, A. | Kornfeld, M. | Thivolet, M. | Gilabert-Perramon, A. | Toumi, M. |
Market access for pharmaceuticals is evolving in a fast-changing environment : (1)Pressure of European Union (EU) Member States (MS) on health insurance budgets; (2) Dramatic technological advances; targeting new biological pathways, advanced therapy medicinal products, personalized medicines, expansion of digital medicine; (3) Initiatives from regulators and payers to develop synergies, e.g., collaborations between HTA agencies and multi-HTA/parallel early advice; (4) Increased payer risk-aversion and increasing products with limited information at launch; (5) Healthcare organisations moving towards integrated healthcare services (6) Ageing population and growing prevalence of chronic conditions, co-morbidities, and life threatening diseases; (7) Increased access inequity between EU MS.